Apeiron Biologics is a biotechnology company located in Vienna, Austria. It was founded by Josef Penninger, currently Director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), and pursues three projects based on some of his work:   APN01: Development of recombinant human Angiotensin Converting Enzyme 2 (rhACE2) for therapy of various diseases with an imbalance of the Renin Angiotensin System Cbl-b: A novel immunotherapeutic approach against cancer via modulation of the autoimmune potential of T cells by inhibition of the E3 ubiquitin ligase Cbl-b DREAM: A new class of analgesics by induction of the expression of an endogenous opioid via targeting of the suppressor protein DREAM